# MIST earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/MIST) · [Earnings tab](https://www.lopjlb.com/stock/MIST?tab=earnings)

Updated: 2026-11-14T06:55:30

Quarters analyzed: 3

## Cross-quarter narrative

Across the three earnings calls Milestone Pharma moved from an early launch phase to a scaling phase for CARDAMYST while tightening its cost base. Q1 highlighted modest script volume (~600) and limited 25% commercial coverage. By Q2 script volume rose above 1,500 with coverage near 50% of commercially insured lives and the company announced a digital patient‑activation campaign. Q3 showed further acceleration, with coverage expanding to roughly two‑thirds of lives, prescriber momentum sustaining, and a cost‑efficiency program targeting a 30% reduction in operating expenses, extending cash runway into late 2028. The AFib‑RVR Phase III trial remained on track throughout, but payer‑coverage timing, Medicare formulary limits, and competitive threats persisted as recurring concerns. New uncertainties emerged around gross‑to‑net assumptions and inventory risk in Q2, while Q3 added focus on national formulary placement and trial readout risk. Overall the narrative reflects improving commercial traction and financial discipline, offset by ongoing payer and competitive headwinds.

## Latest CallCard · Q3

Milestone Pharma reports strong Q3 CARDAMYST launch growth, expanding commercial coverage to two‑thirds, implementing cost cuts to trim operating expenses ~30% by Q1 2027 and extending cash runway to late 2028 while advancing the AFib‑RVR Phase III trial.

**Guidance:** maintained — Management reaffirmed that cost‑efficiency measures will extend operating cash runway into late 2028 and support the anticipated Phase III readout in H2 2028, without altering prior guidance.

**Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3

Prepared remarks highlight prescription growth, broader payer coverage and cost‑efficiency actions, conveying optimism about commercial momentum and long‑term value creation.

### Demand visibility

Commercial formulary coverage now ~66% of lives; national PBM coverage pending; Medicare coverage limited to regional plans.

Coverage grew from ~25% at end‑Q2 to ~50% by August and ~two‑thirds today, but CVS Caremark national placement is still being pursued; Medicare uptake is modest and focused on exception pathways.

### Margins / costs

Cost‑efficiency program targets ~30% operating expense reduction, with $2 M one‑time transition charges.

Measures include bringing 45 contracted reps in‑house, prioritizing high‑impact marketing, reducing HQ staff, and converting infrastructure to Milestone‑owned systems, to be completed by Q1 2027.

### Capital allocation

Capital is being redirected to in‑house sales, high‑value HCP engagement, patient support services and preservation of cash for the AFib‑RVR program.

Transition of field force, expanded patient assistance and copay programs, and continued investment in the ReVeRA‑301 trial reflect a focus on sustainable growth and cash preservation.

### Milestones

- **CARDAMYST Q3 prescription volume** [on_track]: 1,800 scripts in Q3, a 50% QoQ increase, total ~3,400 since launch.
- **Commercial formulary coverage** [on_track]: Coverage expanded to approximately two‑thirds of commercially insured lives.
- **Sales force transition** [on_track]: 45 contracted reps being onboarded as employees; full transition expected Q1 2027.
- **Operating expense reduction** [on_track]: Target ~30% expense cut; $2 M one‑time charges, completion by Q1 2027.
- **ReVeRA‑301 Phase III trial** [on_track]: Enrollment underway in US, Canada, Europe; readout anticipated H2 2028.

### Fears / risks

- **Payer coverage**: National formulary placement with CVS Caremark remains pending, potentially limiting broader commercial uptake.
- **Medicare adoption**: Limited Medicare formulary coverage and reliance on exception pathways create uncertainty for future prescription growth.
- **Clinical trial risk**: Phase III readout of ReVeRA‑301 is a key value driver; any delay or negative outcome could impact long‑term prospects.
- **Cash runway**: Extended runway depends on successful execution of cost‑efficiency measures and continued revenue growth.
- **Competitive landscape**: Emerging therapies for PSVT and AFib‑RVR could affect market share.
- **Fill‑rate performance**: While fill rates are reported as improving, actual data are not disclosed, leaving some execution risk.
- **Regulatory risk**: Ongoing regulatory approvals for new indications carry inherent uncertainty.
- **Operational transition**: Integrating contracted sales force and reducing HQ staff may encounter execution challenges.

### Key quotes

> “We recorded approximately 1,800 prescriptions of CARDAMYST in Q3, representing a 50% increase over the prior quarter”

> “coverage has expanded to approximately two-thirds of commercially insured lives”

> “Net product revenue was $1.0 million for the third quarter of 2026, compared with $0.6 million in the second quarter of 2026” — Anthony Krick

> “we feel very confident that we are benchmarking well against both of those types of analog products, that our fill rates are not the primary obstacle toward growing the drug”

> “we believe the actions we're taking today are necessary to achieve both objectives and position Milestone for long-term value creation”

## Quarter one-liners

- **2026 Q3:** Milestone Pharma reports strong Q3 CARDAMYST launch growth, expanding commercial coverage to two‑thirds, implementing cost cuts to trim operating expenses ~30% by Q1 2027 and extending cash runway to late 2028 while advancing the AFib‑RVR Phase III trial.
- **2026 Q2:** Milestone Pharma reports Q2 2026: CARDAMYST launch shows >800 prescribers, >1,500 scripts H1; commercial coverage jumps to ~50% commercially insured lives; ReVeRA-301 Phase III AFib-RVR trial initiated; cash $170.6M funds ops into H2 2027. H2 acceleration expected from coverage pull-through and pati
- **2026 Q1:** Milestone Pharma reports early CARDAMYST launch traction with ~600 scripts through April, 25% commercial coverage via Express Scripts, and initiated Phase III ReVeRa-301 for AFib-RVR; cash $184M funds ops into H2 2027.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights steady month-over

## Theme arcs

- **Commercial coverage expansion** (improving): Coverage grew from 25% to ~66% of lives across calls
- **Prescriber/script growth** (improving): Scripts increased from ~600 to >1,500
- **Cost‑efficiency program** (new): 30% OPEX reduction announced in Q3
- **Cash runway extension** (improving): Runway pushed to late 2028 after cost cuts
- **AFib‑RVR Phase III trial progress** (stable): Trial initiated in Q1 and remained on track
- **Payer coverage uncertainty** (deteriorating): National formulary placement pending and Medicare limited
- **Competitive landscape risk** (new): Emerging therapies noted as potential threat in Q3
- **Digital patient activation campaign** (new): Introduced in Q2 with uncertain impact

## Fear persistence

- **Coverage scaling uncertainty** [recurring]: Raised in Q2 and again in Q3 regarding national formulary
- **Patient activation impact uncertainty** [new]: Identified in Q2 only
- **Gross‑to‑net pressure** [new]: Analyst probe in Q2, not mentioned later
- **Channel inventory risk** [new]: Raised by analysts in Q2
- **Competitive landscape risk** [recurring]: Discussed in Q2 and Q3 as potential future competition
- **Medicare formulary limitation** [new]: Highlighted as a fear in Q3
- **Clinical trial readout risk** [new]: Phase III outcome risk noted in Q3
- **Cash runway dependency on cost cuts** [new]: Risk emphasized in Q3

## Guidance path

2026 Q1:vague → 2026 Q2:vague → 2026 Q3:maintained

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/MIST`